Author

Balveen Kaur

Louisiana State UniversityORCID 0000-0001-7738-0804Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Bangxing HongiD· 2 shared David H. MunniD· 2 shared Dong Zhu· 2 shared Haocheng DingiD· 2 shared Konstantina KyritsiiD· 2 shared Ravindra B KolheiD· 2 shared Theodore S. JohnsoniD· 2 shared Dongwen LviD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Bangxing HongORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tyrosine hydroxylase–mediated neuroimmune crosstalk regulates antitumor immunity in glioblastoma during oncolytic herpes virotherapy

Konstantina Kyritsi, Haocheng Ding, Dong Zhu, Ravindra B Kolhe, Theodore S. Johnson, Balveen Kaur, David H. Munn, Bangxing Hong

This study shows that tyrosine hydroxylase-mediated neuroimmune signaling in glioblastoma affects antitumor immunity and enhances oncolytic virotherapy efficacy.

bioRxiv · Jun 23, 2026 · PreprintCancer Biology

BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation

Konstantina Kyritsi, Dong Zhu, Haocheng Ding, Gregory K. Friedman, Dongwen Lv, Meng Wang, Nahid F. Mivechi, Ravindra B Kolhe, Theodore S. Johnson, Balveen Kaur, David H. Munn, Bangxing Hong

This study shows that BTK inhibition enhances oncolytic virotherapy in glioblastoma by promoting tertiary lymphoid structure formation and improving immune cell infiltration.

bioRxiv · Jun 4, 2026 · PreprintCancer Biology